

ACELRX PHARMACEUTICALS INC

Form 8-K

February 11, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 5, 2013**

**ACELRX PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State of incorporation)**

**001-35068**  
**(Commission**

**41-2193603**  
**(IRS Employer**

**File No.)**

**Identification No.)**

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

351 Galveston Drive

Redwood City, CA 94063

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 216-3500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.*****2013 Base Salaries***

On February 5, 2013, the Board of Directors (the Board) of AcetRx Pharmaceuticals, Inc. (the Company) approved the 2013 base salaries (effective retroactively to January 1, 2013) for certain of the Company's named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission, the NEOs) in the amounts set forth in the table below.

<b>Named Executive Officer</b>	<b>2013 Base Salary</b>
Richard A. King, Chief Executive Officer	\$ 475,000
James H. Welch, Chief Financial Officer	\$ 307,500
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer	\$ 409,000
Badri Dasu, Chief Engineering Officer	\$ 301,500
Lawrence G. Hamel, Chief Development Officer	\$ 301,000

***Bonus Payments***

On February 5, 2013, the Board approved bonus payments for 2012 performance for certain of the NEOs in the amount set forth in the table below, in accordance with the Company's established 2012 Cash Bonus Plan.

<b>Named Executive Officer</b>	<b>2012 Bonus</b>
Richard A. King, Chief Executive Officer	\$ 170,400
James H. Welch, Chief Financial Officer	\$ 95,232
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer	\$ 134,034
Badri Dasu, Chief Engineering Officer	\$ 95,160
Lawrence G. Hamel, Chief Development Officer	\$ 93,964

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 11, 2013

ACELRX PHARMACEUTICALS, INC.

By: /s/ James H. Welch  
James H. Welch  
Chief Financial Officer